Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Clinicaltrials.gov ID: NCT07492927
db-list-check Status RECRUITING
b-loader Phase
b-people Age ≥ 18 Years
b-bullseye-arrow Enrollments 1700

Conditions

Clinically Significant Prostate Cancer

Summary

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Contact Person

Study Chair

  • Weijun Qin, MD.

Eligibility Criteria

Inclusion Criteria:

1. Blood prostate-specific antigen PSA>4ng/dl;
2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
3. The patient is willing to undergo prostate biopsy.

Exclusion Criteria:

1. Previous diagnosis of prostate cancer through prostate biopsy;
2. History of other malignant tumors in the past two years;
3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment

Study Plan

Study Cohort

The experimental arm receiving diagnosis from serum RNA combination

Outcome Measures

Primary Outcome Measures

The diagnostic efficacy of plasma exo-RNA panel alone in diagnosing csPCa

Time Frame: The time of prostate biopsy

Secondary Outcome Measures

Diagnostic efficacy of plasma exo-RNA panel in diagnosing csPCa and its comparison with other imaging methods or blood tests

Time Frame: The time of prostate biopsy

Timeline

  • Last Updated
    March 25, 2026
  • Start Date
    March 25, 2026
  • Today
    October 1, 2026
  • Completion Date ( Estimated )
    June 30, 2027

Similar Trials

light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years